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The cohort of long-term survivors of heart transplant is expanding, and the assessment of these patients requires specific knowledge of the
surgical techniques employed to implant the donor heart, the physiology of the transplanted heart, complications of invasive tests routinely
performed to detect graft rejection (GR), and the specific pathologies that may affect the transplanted heart. A joint EACVI/Brazilian cardio-
vascular imaging writing group committee has prepared these recommendations to provide a practical guide to echocardiographers involved in
the follow-up of heart transplant patients and a framework for standardized and efficient use of cardiovascular imaging after heart transplant.
Since the transplanted heart is smaller than the recipient’s dilated heart, the former is usually located more medially in the mediastinum and
tends to be rotated clockwise. Therefore, standard views with conventional two-dimensional (2D) echocardiography are often difficult to
obtain generating a large variability from patient to patient. Therefore, in echocardiography laboratories equipped with three-dimensional
echocardiography (3DE) scanners and specific expertise with the technique, 3DE may be a suitable alternative to conventional 2D echocar-
diography to assess the size and the function of cardiac chambers. 3DE measurement of left (LV) and right ventricular (RV) size and function are
more accurate and reproducible than conventional 2D calculations. However, clinicians should be aware that cardiac chamber volumes
obtained with 3DE cannot be compared with those obtained with 2D echocardiography. To assess cardiac chamber morphology and function
during follow-up studies, it is recommended to obtain a comprehensive echocardiographic study at 6 months from the cardiac transplantation
as a baseline and make a careful quantitation of cardiac chamber size, RV systolic function, both systolic and diastolic parameters of LV function,
and pulmonary artery pressure. Subsequent echocardiographic studies should be interpreted in comparison with the data obtained from the
6-month study. An echocardiographic study, which shows no change from the baseline study, has a high negative predictive value for GR. There
is no single systolic or diastolic parameter that can be reliably used to diagnose GR. However, in case several parameters are abnormal, the
likelihood of GR increases. When an abnormality is detected, careful revision of images of the present and baseline study (side-by-side) is highly
recommended. Global longitudinal strain (GLS) is a suitable parameter to diagnose subclinical allograft dysfunction, regardless of aetiology, by
comparing the changes occurring during serial evaluations. Evaluation of GLS could be used in association with endomyocardial biopsy (EMB) to
characterize and monitor an acute GR or global dysfunction episode. RV size and function at baseline should be assessed using several
parameters, which do not exclusively evaluate longitudinal function. At follow-up echocardiogram, all these parameters should be compared
with the baseline values. 3DE may provide a more accurate and comprehensive assessment of RV size and function. Moreover, due to the
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unpredictable shape of the atria in transplanted patients, atrial volume should be measured using the discs’ summation algorithm (biplane
algorithm for the left atrium) or 3DE. Tricuspid regurgitation should be looked for and properly assessed in all echocardiographic studies.
In case of significant changes in severity of tricuspid regurgitation during follow-up, a 2D/3D and colour Doppler assessment of its severity
and mechanisms should be performed. Aortic and mitral valves should be evaluated according to current recommendations. Pericardial effusion
should be serially evaluated regarding extent, location, and haemodynamic impact. In case of newly detected pericardial effusion, GR should be
considered taking into account the overall echocardiographic assessment and patient evaluation. Dobutamine stress echocardiography might be
a suitable alternative to routine coronary angiography to assess cardiac allograft vasculopathy (CAV) at centres with adequate experience with the
methodology. Coronary flow reserve and/or contrast infusion to assess myocardial perfusion might be combined with stress echocardiography to
improve the accuracy of the test. In addition to its role in monitoring cardiac chamber function and in diagnosis the occurrence of GR and/or CAV,
in experienced centres, echocardiography might be an alternative to fluoroscopy to guide EMB, particularly in children and young women, since
echocardiography avoids repeated X-ray exposure, permits visualization of soft tissues and safer performance of biopsies of different RV regions.
Finally, in addition to the indications about when and how to use echocardiography, the document also addresses the role of the other cardio-
vascular imaging modalities during follow-up of heart transplant patients. In patients with inadequate acoustic window and contraindication to
contrast agents, pharmacological SPECT is an alternative imaging modality to detect CAV in heart transplant patients. However, in centres
with adequate expertise, intravascular ultrasound (IVUS) in conjunction with coronary angiography with a baseline study at 4–6 weeks and at
1 year after heart transplant should be performed to exclude donor coronary artery disease, to detect rapidly progressive CAV, and to provide
prognostic information. Despite the fact that coronary angiography is the current gold-standard method for the detection of CAV, the use of IVUS
should also be considered when there is a discrepancy between non-invasive imaging tests and coronary angiography concerning the presence of
CAV. In experienced centres, computerized tomography coronary angiography is a good alternative to coronary angiography to detect CAV. In
patients with a persistently high heart rate, scanners that provide high temporal resolution, such as dual-source systems, provide better image
quality. Finally, in patients with insufficient acoustic window, cardiac magnetic resonance is an alternative to echocardiography to assess cardiac
chamber volumes and function and to exclude acute GR and CAV in a surveillance protocol.
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Abbreviations
GR graft rejection
CAV cardiac allograft vasculopathy
CFR coronary flow reserve
CMR cardiac magnetic resonance
CT computed tomography
DTI Doppler tissue imaging
EACVI European Association of Cardiovascular Imaging
EF ejection fraction
EMB endomyocardial biopsy
FFR fractional flow reserve
GLS global longitudinal strain
HT heart transplantation
HHT heterotopic heart transplantation
ISHLT International Society for Heart and Lung Transplantation
IVRT isovolumetric relaxation time
IVUS intravascular ultrasound
LV left ventricle/ventricular
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RV right ventricle/ventricular
SR strain rate
STE speckle tracking echocardiography
TAPSE tricuspid annular plane systolic excursion
Introduction
Heart transplantation (HT) represents the mainstream therapy of
end-stage heart failure, providing a 90% 1-year survival after sur-
gery.1,2 More than 4000 HT are performed each year in over 300
countries.3 However, despite advances in surgical techniques, diag-
nostic approaches, and immunosuppressive strategies, survival after
HT continues to be limited by the development of acute/chronic
graft rejection (GR) and cardiac allograft vasculopathy (CAV), which
represent the leading causes of morbidity and mortality in these pa-
tients.4,5 Since GR is usually an asymptomatic, rapid onset condition
bearing a poor prognosis, regular surveillance of HT patients is man-
datory, particularly in the first year after HT. In contrast with the
rather rapid course of acute GR, CAV is a progressive process
that develops over the years, usually without symptoms. Currently,
the reference modalities to detect acute GR and CAV are endomyo-
cardial biopsy (EMB) and coronary angiography, respectively.4 How-
ever, both modalities are invasive and expensive, and are associated
with non-negligible risk. Although uncommon, EMB complications,
including myocardial perforation, pericardial tamponade, arrhyth-
mias, access-site complications, and iatrogenic tricuspid valve injury
leading to significant regurgitation, may occur at a rate of 0.5–
1.5%.6 – 8 Moreover, EMB may not detect GR in up to 20% of pa-
tients, due to sampling errors (related to the patchy nature of
GR), variability in the interpretation of histological findings, and
lack of routine screening for antibody-mediated rejection.9 Routine
coronary angiography used for detecting CAV carries a small, but
not negligible risk of complications, such as stroke, heart perfor-
ation, coronary artery dissection, and allergic reactions to intraven-
ous contrast.10 Furthermore, routine coronary angiography should
preferably not be performed in patients with moderate to severe
chronic kidney disease because of the risk of acute kidney injury
(relative contraindication in patients with renal dysfunction).11
During the last decade, many efforts have been made in an at-
tempt to create a new non-invasive strategy to detect GR and
CAV. Several non-invasive cardiovascular imaging modalities and
bio-molecular medicine techniques have been tested, including
echocardiography, radionuclide imaging, cardiac magnetic reson-
ance (CMR), intramyocardial electrogram recording, immunologic
monitoring, gene expression profile, and biohumoral factors. None-
theless, current guidelines for the management of heart transplant
patients4 state that no alternative strategy either based on imaging
(e.g. echocardiography, CMR) or biomarkers (e.g. natriuretic pep-
tides, cardiac troponins, and C-reactive protein) can be recom-
mended as an alternative to EMB for GR monitoring (Class III;
level of evidence: C).
Nevertheless, echocardiography remains the most useful imaging
modality to assess and monitor HT patients, as it is widely available,
cheap, can be easily and rapidly performed, is safe for both opera-
tors and patients, well tolerated, and not associated with the risks
of the invasive procedures. Moreover, recent development of
new echocardiographic techniques has increased the likelihood of
detecting graft dysfunction at an early stage.
Accordingly, the European Association of Cardiovascular Imaging
(EACVI) and the Brazilian Cardiovascular Imaging Department de-
veloped this document to review and summarize the most recent
evidence about the non-invasive assessment of patients who under-
went HT, the diagnosis of CAV and acute/chronic GR, with the
intent to set up a framework for standardized and efficient use of
cardiovascular imaging after HT.
Heart transplantation
Surgical techniques and outcome
Orthotopic heart transplantation
Currently, the bicaval technique (five anastomoses) is the most
frequently used surgical technique to perform orthotopic heart
transplant (OHT), followed by the standard technique and the total
OHT technique. The three techniques were used in 62, 34.7, and
,3% of the OHT performed in 2007, respectively.12,13
The standard technique, also known as biatrial technique, was the
first surgical approach used for OHT.12,13 It entailed simple anasto-
moses at the mid-level of the left and right atria in addition to the
aortic and pulmonary artery anastomoses just above the semilunar
valves14,15 (Figure 1A). In addition, the atrial appendages are removed
to decrease the risk of post-operative thrombus formation. How-
ever, since the right atrial incision is usually close to the donor sino-
atrial node, the necrosis of the sinoatrial node with post-operative
sinus node dysfunction is a frequent complication. Moreover, with
the standard technique, atrial geometry is grossly distorted, result-
ing in enlarged atria with a ‘snowman’ shape due to redundant atrial
tissue16 (Figure 2).
With the bicaval technique17 – 19 (Figure 1B), the surgeon per-
forms separate superior and inferior vena cava anastomoses instead
of the right atrial anastomosis. The left atrial incision is carried to the
base of the left atrial appendage, which is removed leaving a small
margin of the atrial cuff around the four pulmonary veins. The
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main advantage of the bicaval technique is to retain normal shaped
atria, which may preserve atrial and sinus node function.
The total OHT technique (Figure 1C) is a complete atrioventricular
cardiac transplantation with separate caval and pulmonary vein
anastomoses.20 This technique, while carrying similar advantages
to the bicaval operation, presents many technical issues, as bleeding
from the suture lines of pulmonary veins and reduced patency of
pulmonary veins due to twisting or stenosis at the level of the anas-
tomoses, that may prolong the procedure and increase operative
complication rates.12 Therefore, it is seldom employed today.
Outcome of OHT performed with the different techniques has
been compared in several studies with conflicting results. Most
data, however, indicate that the bicaval and the total OHT techni-
ques are more physiological than the biatrial method. The first men-
tioned methods preserve sinoatrial node function and require less
pacemaker implants.13,21,22 Tricuspid valve regurgitation is also
significantly lower with these techniques, whereas no effect has
been demonstrated on the incidence of mitral regurgitation.21,22
However, a true comparison between techniques is difficult, as
the haemodynamic measurements were recorded at various inter-
vals ranging from days to years post-operatively.
Specific complications for each technique have been documen-
ted. Standard technique may trigger arrhythmias and also promote
atrial thrombi formation,21,23 whereas in patients who underwent
bicaval or total OHT techniques, superior vena cava stenosis may
occur with an overall incidence of 2.4%.24
Overall, there is a general consensus about the superiority of the
bicaval technique due to the presence of normal right and left atrial
sizes, lower right heart filling pressures, and almost normal flows in
the caval veins post-operatively.21,25,26
Heterotopic heart transplantation
Heterotopic heart transplant (HHT) refers to the placement of a
donor heart without recipient cardiectomy.27 Anatomically, the
allograft is placed to the right of the native heart in the right chest
to avoid compression by the sternum and at an angle close to 908
to the native heart to allow for the widest possible connection
between the native and donor atria. The donor’s superior vena
cava is attached to the recipient’s right atrium so that blood from
the body now flows to both hearts. A graft from one of the donor’s
blood vessels connects the donor’s and recipient pulmonary arter-
ies, allowing both hearts to send blood to the lungs. Donor’s and
recipient’s left atria are connected so that blood from the lungs tra-
vels to both hearts. The donor heart is attached to the recipient’s
aorta to transport blood from both hearts out to the body (Figure 3).
There are several recognized complications related to HHT. An
early post-operative complication is compression of the right mid-
dle and right lower lobes of the lung by the allograft, leading to atel-
ectasis, infection, and impaired ventilation. Premature deterioration
of the recipient heart is often observed.28,29 Due to frequent dys-
rhythmias and different flow conditions, thromboembolic events
may occur at an increased rate by leaving the often dilated native
heart in place.30,31
Compared with OHT, preservation of the ‘preconditioned’ native
right ventricle (RV) seemed to offer better survival to recipients
with severe pulmonary hypertension.32,33 Despite being rarely
used today, the heterotopic approach remains a valuable option in
recipients with high irreversible transpulmonary pressure gradients
and expands the donor pool through use of undersized or
Figure 1 Surgical techniques used in orthotopic cardiac trans-
plantation. Ao, aorta; IVC, inferior vena cava; LAC, left atrial cuff;
LPVC, left pulmonary veins cuff; PA, pulmonary artery; RA, right
atrium; RPVC, right pulmonary veins cuff; SVC, superior vena cava.
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otherwise compromised allografts.34,35 However, survival is poorer
in HHT recipients, and with improving results in continuous flow
ventricular assist devices, many patients can be bridged to normal-
ization of pulmonary artery pressures, allowing OHT.36
Heart–lung transplantation
Heart–lung transplantation (cardiopulmonary transplantation) recipi-
ents receive an ‘en bloc’ harvested heart and lung allograft, performing
tracheal, right atrial, and aortic anastomosis using cardiopulmonary
bypass support during surgery. Care is taken to preserve the donor
phrenic nerves and to address the bronchial artery circulation.
The follow-up of heart– lung transplant recipients is similar to
that of double and single lung transplant patients. The majority of
the post-operative complications, including acute and chronic GR,
and infections are related to the lung allograft, not to the cardiac
allograft. Isolated acute GR of the heart, however, is infrequent
and much less common than after single HT.37 – 39 Therefore,
most centres do not recommend EMB for routine heart– lung trans-
plantation surveillance after 4–6 months follow-up.40 However,
recommended non-invasive surveillance protocol for acute and
chronic cardiac GR in heart– lung transplant is the same as for single
HT. The 1-year survival rate after a heart–lung transplant is 65%; the
Figure 2 Two- and three-dimensional echocardiography acquisitions in a patient who underwent heart transplant using the standard technique.
Both the left and right atria are grossly enlarged and the atrial sutures (arrows) are visualized giving the left atrium the typical ‘snowman’ shape.
Arrow, suture lines, Ao, aorta, LA, left atrium; LV, left ventricle; MV, mitral valve; RA, right atrium.
Figure 3 Schematic drawing of the connections between the
native and the donor heart in heterotopic heart transplantation.
AO, aorta; LA, left atrial; LV, left ventricle; PA, pulmonary artery;
RV, right ventricle; SVC, superior vena cava.
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5-year survival rate is 40%.41 Early mortality is secondary to surgical
losses and acute allograft failure. The late attrition is due to oblitera-
tive bronchiolitis (the chronic GR process of the lung) and rejection.
Physiology of the transplanted heart
Despite the donor’s heart function is usually normal, the particular
cardiovascular physiology of cardiac allograft (afferent and efferent
allograft denervation) and surgical complications (myocardial injury
and maladaptation that occur at the time of organ harvest, subsequent
rejection injuries) determine the peculiar haemodynamic conditions
observed in HT recipients. In addition, pre-existing, undetected, do-
nor cardiac pathologies may also affect transplanted heart function.
Cardiac denervation is an inevitable consequence of HT, as the
cardiac plexus is divided in the donor, resulting in a denervated do-
nor heart.42 With the standard technique, the atrial remnant of the
recipient remains innervated, but no impulse will cross the suture
line. As a result, the donor atrium is responsible for heart beat gen-
eration in the implanted hearts independent on the surgical tech-
nique, and it beats at a higher intrinsic rate (90–110 bpm) and
shows reduced heart rate variability. Normal heart rate responses
to postural changes and heart rate variations in response to stimuli
such as the Valsalva manoeuvre and carotid sinus massage are re-
duced. Drugs or manoeuvres that act via autonomic nerve fibres
are also ineffective. However, the heart retains its responsiveness
to direct acting agents such as isoproterenol, epinephrine, norepin-
ephrine, dopamine, and dobutamine.
Intrinsic cardiac functions such as impulse formation and conduc-
tion and Frank–Starling mechanism are preserved. Therefore, the
initial response to Frank–Starling in a denervated heart is an in-
crease in stroke volume, which is critically dependent on an ad-
equate left ventricular (LV) end-diastolic volume. The increase in
contractility secondary to increased heart rate is a secondary effect
and is dependent on circulating catecholamines. The transplanted
heart is, therefore, critically preload dependent, and higher filling
pressures are needed to maintain a normal stroke volume.
In patients who underwent OHT using the standard technique,
atrial mechanics is impaired, apparently due to the mid-atrial anasto-
moses between the donor and the recipient hearts. Assessment of
LV diastolic function in the transplanted heart is challenging, because
sinus tachycardia of the denervated heart often induces merging of
E and A waves. In addition, after standard technique, the sinus nodes
of the donor and recipient remain intact, with two P waves present
on the electrocardiogram up to 3 weeks after surgery, and both do-
nor and the remaining recipient atria may trigger mechanical activity
provoking important variations in the transmitral E and A velocities.
Moreover, adequate transthoracic recording of pulmonary venous
flow is technically demanding after HT, and pulmonary vein flow vel-
ocities are often altered by residual recipient atrial tissue contrac-
tion that usually occurs at early ventricular filling decreasing the
systolic flow component. Finally, end-diastolic atrial contraction
will increase pulmonary vein atrial reversal wave (Ar wave) velocity.
As a result, the atrial contribution to net stroke volume is generally
reduced compared with normal subjects. Bicaval and total HT tech-
niques should provide better atrial mechanics and function, achiev-
ing greater left atrial emptying force and more physiological
atrioventricular coupling.26
Usually, HT patients show restrictive physiology early after the
transplant operation, which tends to improve during the follow-
up.43,44 However, early haemodynamic studies conducted in
‘healthy’ OHT patients reported normal intracardiac pressures at
rest, but dramatic increase in LV end-diastolic pressure during exer-
cise, suggesting an occult rather than absent restrictive pattern.45 As
a further confirmation, the first sign of the onset of acute GR is often
overt restrictive physiology.46
Early allograft failure
Early allograft failure is the main cause of death in the first 30 days
after HT and remains an important cause of death throughout the
post-transplant period.5 Main features of early allograft failure are
LV or biventricular dysfunction with hypotension, low cardiac out-
put, and high filling pressures. Graft failure is defined as primary in
the absence of obvious anatomic or immunologic cause, or as sec-
ondary when it can be attributed to reperfusion injury, unresponsive
pulmonary hypertension, immunologic cause, or hyperacute rejec-
tion.5,47,48 Echocardiographic evaluation demonstrate reduced glo-
bal myocardial function [LV ejection fraction (EF) , 45%], loss of
contractile reserve, and increased RV volume with systolic dysfunc-
tion [tricuspid annulus plane systolic excursion (TAPSE) , 15 mm
or a RV EF, 45%].
Reperfusion injury during surgery results from prolonged cold is-
chaemia time and/or reperfusion ischaemia. It may be transient
(myocardial stunning), lasting 12–24 h after HT or may trigger early
allograft failure after surgery.49 Prolonged cold ischaemia time (long-
er than 5 h) has been associated with higher incidence of allograft
dysfunction and is a significant cause of early allograft failure.50,51
Hyperacute rejection is an extremely rare condition that occurs
within the first 24 h after HT. The hyperacute rejection is the most
ominous cause of perioperative LV dysfunction. It is initiated by pre-
formed recipient antibodies (IgG or IgM) that cross-react with
endothelial epitopes on the allograft, promoting widespread endo-
thelial damage leading to global ischaemia and catastrophic allograft
failure.52 Hyperacute rejection is most often observed after implant-
ation of an ABO-mismatched heart, or in highly sensitized patients,
such as multiparous women or patients who underwent multiple
blood transfusions.52
Isolated RV failure occurring in the operating room or detected
by echocardiography performed during the first 48 h after surgery
is defined by the presence of a TAPSE , 15 mm or a RV EF,
45% alongside normal or near-normal LV systolic performance, in
the absence of other obvious causes of graft dysfunction triggering
severe haemodynamic instability. RV failure accounts for 50% of
all cardiac complications and 19% of death in the early period
after HT.53 – 55 Acute changes in haemodynamics after HT mainly
affect RV function. Several factors may influence donor RV function
after HT: (i) organ preservation, affecting donor RV contractility;
(ii) pre-existing and underestimated pulmonary hypertension of
the recipient; and (iii) cardiopulmonary bypass, which may increase
pulmonary vascular resistances particularly in patients with
abnormal pre-operative values.
Acute graft rejection
Acute graft rejection is the leading cause of mortality during the first
year after HT. Its incidence is around 20–40% and is responsible for
L.P. Badano et al.924
12% of all fatalities.5 Acute GR is caused by a recipient
alloimmune-dependent process directed against donor major histo-
compatibility complex antigens, or peptides presented by dendritic
cells. Acute GR is categorized into acute cellular or antibody-
mediated rejection.56,57 Acute cellular rejection is well character-
ized and graded according to established histological criteria—Inter-
national Society for Heart and Lung Transplantation (ISHLT)
classification of body specimen, established in 1990 and then revised
in 2004 (Table 1).58 Antibody-mediated rejection is less well charac-
terized; the diagnosis is made on a number of histological and/or im-
munopathological features without standardized diagnostic criteria.
Recently, the ISHLT has addressed this issue and a new grading sys-
tem has been proposed.59 However, further work is required to test
its consistency and reproducibility.
Most cases of acute cellular rejection are diagnosed by routine
surveillance ‘protocol’ of frequent EMB, even if the patient is asymp-
tomatic and LV EF remains in the normal range.5,54 Sampling error
associated with the patchy nature of acute rejection, variability in the
interpretation of histological findings, and non-routine screening for
antibody-mediated rejection may result in underestimation of the
severity or miss the diagnosis of acute cellular rejection. As a result,
the absence of pathologic evidence for severe rejection in the pres-
ence of otherwise unexplained LV dysfunction, heart failure, or
shock should not prevent treatment for rejection. Symptoms usually
develop only when the heart damage is extensive.
Chronic graft rejection
Chronic rejection is mainly determined by CAV and is characterized
by a fibro-proliferative process affecting cardiac blood vessels,
resulting in concentric narrowing and obliteration of coronary ves-
sels. CAV has been reported to occur in 20% of patients after
3 years, 30% at 5 years, and up to 50% after 10 years.5 Recurrent
acute antibody-mediated GR increases the risk of CAV. Initially,
CAV is a diffuse process affecting the large epicardial coronary arter-
ies, the coronary veins, and the microcirculation; later, CAV may
also cause focal luminal stenosis.60 Histologically, CAV is character-
ized by concentric fibrous intimal hyperplasia and smooth muscle
cell proliferation. ISHLT has defined CAV based on visual coronary
angiographic stenosis parameters along with LV EF plus LV diastolic
function assessment (Table 2).61
Diagnosis of CAV is usually made by coronary angiography and
echocardiographic assessment of allograft function. However, angi-
ography may provide a gross underestimation of this diffuse and
concentric vasculopathy. Because of these limitations, alternative
imaging modalities, such as intravascular ultrasound (IVUS) and frac-
tional flow reserve (FFR), have been proposed to improve the sen-
sitivity for CAV detection. However, even if IVUS is considered the
most sensitive technique for detecting the anatomic features
of CAV, its application is limited by its costs and lack of widespread
expertise with this imaging technique.
Cardiac interstitial fibrosis, which leads to ventricular stiffness and
diastolic dysfunction of the graft, is typically monitored by repeated
EMBs.62 However, this invasive procedure often fails to detect
patchy cardiac interstitial fibrosis at an early stage of its evolution.
Of note, in some patients, chronic GR may also be triggered by
recurrent, chronic immune response against the transplanted heart,
which gradually impairs myocardial function by replacing myocardial
cells with fibrous tissue.
Graft dysfunction due to other aetiologies
Other causes of graft dysfunction, mimicking GR and CAV, have
been reported. The most common of them are cytomegalovirus,
Toxoplasma gondii and coxsackievirus infections, as well as Chagas
disease (Trypanosoma cruzi) reactivation and/or myocarditis. No car-
diac imaging finding has been found to be diagnostic of a specific
aetiological cause. In case of a graft dysfunction, serological and
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 International Society of Heart and Lung Transplantation classification of acute allograft rejection
1990 Classification 2005 Revised classification
Grade 0 No rejection Grade 0 R No rejection
Grade 1 (mild) Grade 1 R (mild) Interstitial and/or perivascular infiltrate with up to
1 focus of myocyte damage
1A: Focal Focal perivascular and/or interstitial infiltrate without
myocyte damage
1B: Diffuse Diffuse infiltrate without myocyte damage
Grade 2 (moderate) One focus of infiltrate with associated myocyte damage
Grade 3 (moderate) Grade 2R
(moderate)
Two or more foci of infiltrate with associated
myocyte damage
3A: Focal Multifocal infiltrate with myocyte damage
3B: Diffuse Diffuse infiltrate with myocyte damage Grade 3R (severe) Diffuse infiltrate with multifocal myocyte damage.
Oedema, haemorrhage, and vasculitis may be
present
Grade 4 (severe) Diffuse, polymorphous infiltrate with extensive myocyte
damage. Oedema, haemorrhage, and vasculitis may be
present
Adapted from Stewart et al.58
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specific immunohistochemistry testing is necessary for accurate
aetiological diagnosis.4,63,64
Infective endocarditis in heart transplant
patients
There are limited data about the incidence and prognosis of infective
endocarditis after HT. Even in the ESC guidelines on prevention,
diagnosis, and treatment of infective endocarditis,65 this condition
is not mentioned. However, it has been reported that the incidence
of infective endocarditis among HT recipients was 50/110-fold
higher than in the general population.66,67 Possible explanations
for this markedly increased incidence include catheter-related and
other nosocomial blood stream infections, LV assist device-related
mediastinitis, donor heart contamination, deep wound infections
following transplant, EMB, and suppression of cell-mediated immun-
ity. Forty to fifty per cent of patients had tricuspid valve infection.
This rate of tricuspid involvement approaches that in intravenous
drug users with endocarditis. Aziz et al.68 reported a 0% bacter-
aemia rate just prior to EMB, but a 70% rate of coagulase-negative
Staphylococcus bacteraemia in atrial blood immediately following
the biopsies. Despite the fact that it seems that increased numbers
of EMB were associated with tricuspid valve infection, the true role
of EMB (as opposed to catheter-related and other blood stream in-
fections) as a predisposition to infective endocarditis remains un-
defined. In the reported series, the most common pathogens
were Staphylococcus aureus (40% of cases) and Aspergillus fumigatus
(30% of post-transplant endocarditis). All patients who developed
A. fumigatus endocarditis following HT had antecedent Cytomegalo-
virus viremia. This finding suggests that patients with A. fumigatus in-
fection had heightened immunosuppression prior to infective
endocarditis. In literature, mortality of HT patients with infective
endocarditis ranges from 22 to 80%, with a peak rate of 100%
endocarditis-related mortality in Aspergillus infective endocarditis
following HT.66
The prevalence of endocarditis is high in HT recipients, and it
should be treated promptly because of a high mortality rate. There-
fore, a high score of suspicion should be used in this specific popu-
lation. Echocardiography should be performed rapidly to exclude
the diagnosis and even repeated when initial echocardiographic




Echocardiography is the first line imaging modality to assess HT pa-
tients, providing accurate information about graft anatomy and func-
tion, which is part of all serial evaluations during post-transplant
follow-up.4 The ISHLT Guidelines for Heart Transplant Recipients
do not specify the timing of echocardiographic evaluations and do
not recommend echocardiography as an alternative to serial EMB
in rejection monitoring.4 Nevertheless, echocardiography is com-
monly used when there is a high clinical suspicion of acute GR des-
pite negative EMB findings and to monitor LV function during
confirmed GR episodes.
In the immediate post-operative period, echocardiography
enables identification of surgical complications and early allograft
dysfunction, while in long-term follow-up, serial echocardiographic
studies are useful to detect acute GR (Figure 4), CAV (Figure 5), and
to monitor pulmonary artery systolic pressure. A main technical is-
sue is that echocardiographic parameters are more variable
in HT patients than in the general population. This fact makes it
difficult to define ‘normal’ transplanted heart morphology and
function and to identify appropriate cut-off values for the different
echocardiographic parameters to detect allograft dysfunction.69
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No detectable angiographic lesion
ISHLT CAV1 (mild) Angiographic left main stenosis of ,50%, or primary vessel with maximum lesion of ,70%, or any branch stenosis ,70%
(including diffuse narrowing) without allograft dysfunction
ISHLT CAV2 (moderate) Angiographic left main stenosis of ≥50%; a single primary vessel ≥70%, or isolated branch stenosis ≥70% in branches of two
systems, without allograft dysfunction
ISHLT CAV3 (severe) Angiographic left main stenosis of ≥50%, or two or more primary vessels ≥70% stenosis, or isolated branch stenosis ≥70% in
all three systems; or ISHLT CAV1 or CAV2 with allograft dysfunction (defined as LVEF ≤ 45%, usually in the presence of
regional wall motion abnormalities) or evidence of significant restrictive physiology (which is common but not specific)
Definitions:
(1) A ‘primary vessel’ denotes the proximal and middle 33% of the left anterior descending artery, the left circumflex, the ramus, and the dominant or
co-dominant right coronary artery with the posterior descending and posterior branches;
(2) A ‘secondary branch vessel’ includes the distal 33% of the primary vessels or any segment within a large septal perforator, diagonals and obtuse
marginal branches, or any portion of a non-dominant right coronary artery;
(3) Restrictive cardiac allograft physiology is defined as symptomatic heart failure with echocardiographic E to A velocity ratio .2 (.1.5 in children),
shortened isovolumetric relaxation time (,60 ms), shortened deceleration time (,150 ms), or restrictive haemodynamic values (right atrial
pressure .12 mmHg, pulmonary capillary wedge pressure .25 mmHg, cardiac index ,2 l/min/m2)
Adapted from Mehra et al.61
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Therefore, in this special population, having a comprehensive indi-
vidual baseline echocardiographic study available for comparison
during the serial follow-up studies is more useful than the absolute
value of each measurement.70 Such a baseline echocardiographic as-
sessment should be performed after at least 6 months from the HT
procedure. Earlier after HT, the adaptation of the new heart to the
thoracic space, its different positioning in the chest compared with
the native heart, and the presence of confounders such as early allo-
graft dysfunction, pericardial effusion, and other co-morbidities (e.g.
sepsis, mechanical complications of EMB, and multiple organ
dysfunction) may affect the recorded echocardiographic parameters
and decrease the sensitivity of echocardiography to detect acute
GR during follow-up.71
Timing of echocardiographic assessment
and acquisition protocol
Due to the lack of evidences about the optimal timing of echocar-
diographic studies in HT patients, this writing committee reached a
consensus on recommending echocardiographic evaluations as de-
scribed in Figures 4 and 5.
Figure 4 Flow chart summarizing the timing and imaging modalities used to monitor allograft dysfunction after heart transplant. CMR, cardiac
magnetic resonance; EMB, endomyocardial biopsy; GR, graft rejection *Allograft dysfunction: a confirmed, reported echocardiographic evaluation,
drop of the left ventricular ejection fraction of more than 10 percent points to a value less than 50% compared to 6th month baseline evaluation
§Patients with suspected or confirmed allograft dysfunction: new symptoms of possible cardiac dysfunction; ECG changes.
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As the donor heart is normal in size, it is smaller than the original
recipient dilated heart; therefore, it is located more medially in the
mediastinum and tends to be rotated clockwise. Due to this rotation
and medial displacement in some patients, standard transthoracic
views are obtained from non-standard transducer positions, with
variability from patient to patients.
Standard echocardiographic evaluation protocol should include
two-dimensional (2D) as well as spectral and colour Doppler im-
aging (Tables 3 and 4). In case of abnormalities of graft geometry
or function, additional views and acquisitions are often required.
In all studies, it is necessary to measure the size of the four cardiac
chambers and great vessels, assess LV and RV function, assess heart
valve function, estimate pulmonary artery systolic pressure, and de-
scribe the pericardium (Table 5). To address specific clinical ques-
tions and to improve sensitivity in detecting morpho-functional
changes in the transplanted hearts, laboratories that have the tech-
niques and expertise in using them can employ advanced echocar-
diographic techniques (Table 6).
Cardiac chamber morphology and
function
LV geometry and systolic function
During the first month after HT, the LV morphology is characterized
by an increase in LV mass and in wall thickness,72 that is likely to be
caused by inflammatory cell infiltration and graft oedema. LV wall
thickness usually tends to decrease after 3 months, probably due
to liquid reabsorption.
During long-term follow-up, a secondary increase in LV mass and
wall thickness may occur as a consequence of many factors such as
repetitive rejection episodes, chronic tachycardia, and systemic
hypertension, usually induced by immunosuppressive agents.73
The increase in LV mass and wall thickness has also been described
during acute GR episodes74 probably secondarily to myocardial in-
flammation which induces cellular oedema. However, several re-
ports demonstrate a low sensitivity of this parameter because of
the fluctuation of wall thickness related to scattered acute rejection
cellular oedema pattern combined with immunosuppressive ther-
apy antiedemigen effect.75,76 The recommendation is to monitor
wall thickness during follow-up. Sudden and evident changes in LV
mass and/or wall thickness should raise suspicion of acute GR.
Usually, in patients with uncomplicated HT, LV dimensions
remain within the normal range, as demonstrated in a 10- to
15-year follow-up study.73
LV pump function is usually normal after HT. Despite being
the strongest predictor of outcome in HT patients,77 LV EF is
not an early indicator of graft dysfunction and usually does not
correlate with the grade of rejection found at the EMB. Moreover,
LV EF is an insensitive marker of acute GR.78 Late reduction of LV EF
is often associated with progression of CAV and carries a poor
prognosis.73
Figure 5 Flow chart summarizing the timing and imaging modalities used to monitor cardiac allograft vasculopathy after heart transplant. CAV,
cardiac allograft vasculopathy; CT, computerized tomography; IVUS, intravascular ultrasound; SPECT, Single Photon Emission Computerized
Tomography.
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Table 3 Two-dimensional echocardiography views, acquisition techniques, and parameters to be routinely assessed
in patients who underwent heart transplant
Continued
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New wall motion abnormalities have been reported to be
associated with the presence of CAV yielding a low sensitivity but
a high specificity (69–100%).79 Detection of new wall motion ab-
normalities at rest should raise suspicion of progression of CAV, en-
couraging further tests to rule out this hypothesis. Side-by-side
visualization of the current echocardiographic study with a previous
one (or baseline one) will increase both sensitivity and specificity of
new wall motion abnormality detection.
LV diastolic function
Changes in LV diastolic function are a more sensitive marker of
acute GR than the reduction of LV EF. Early investigators found a
clear relationship between severe impairment of diastolic function
and development of graft failure.46 Evidences that have been col-
lected so far suggest that rejection episodes may alter the diastolic
dynamics of the heart earlier than the EF.80 This is probably caused
by myocardial oedema or by initial fibrosis, which stiffens the LV
myocardium. Impairment of diastolic function has been reported
during episodes of acute GR with a subsequent improvement after
effective treatment.81,82 A stiffer heart may also result from chronic
GR. Moreover, diastolic dysfunction with a preserved LV EF has
been associated with worse long-term prognosis, development of
heart failure symptoms, higher number of rejection episodes and cu-
mulative immune-mediated graft damage.46 Unfortunately, studies
that attempted to correlate indexes of diastolic function (including
pulmonary vein flow pattern, transmitral velocity of propagation)
and myocardial performance index (MPI) with acute GR episodes
have shown conflicting results. Table 7 summarizes the accuracy
of different echocardiographic techniques to detect acute GR.
Doppler indices of mitral inflow have been the most widely inves-
tigated parameters. The filling pattern is usually more preserved in
the bicaval technique surgery, because with this technique atrial
contraction is kept more physiologic. Mena et al92 performed a sys-
tematic review and found 19 good quality studies from 1985 to 2005
about the use of transmitral Doppler diastolic indexes (E wave,
A wave, E/A ratio, deceleration time, isovolumic relaxation time)
in predicting acute GR. They were unable to demonstrate any
significant correlation between variations of LV filling parameters
and proved acute GR. Other studies evaluated pulmonary vein
flow parameters and mitral inflow propagation velocity, but again
they were unable to demonstrate any clear correlation between
these parameters and acute GR severity.71,90 Moreover, these para-
meters have been reported to be abnormal even in some ‘healthy’
HT patient.46 Unfortunately, the assessment of LV filling is affected
by many variables, including pre-load conditions, atrial dynamics and
morphology (dissociation of recipient and donor atrial contraction),
LV compliance and contractility, end-systolic volume, and heart rate.
Therefore, diastolic function may be impaired by different reasons
and is therefore not specific to rejections. Finally, high heart rate,
usually present in the denervated heart, makes the assessment of
diastolic function more difficult due to the frequent fusion of E
and A waves. Nevertheless, we recommend to continue evaluating
diastolic parameters, because the occurrence of diastolic dysfunc-
tion carries significant prognostic value93 in any case and because
the diagnosis of acute GR becomes increasingly accurate when
additional echocardiographic parameters are impaired.
Based on the concept that GR affects both LV and RV diastolic
and systolic function simultaneously, MPI has been proposed as an
early marker of rejection in HT patients. At present, the accuracy
of MPI to detect acute GR in HT patients is controversial.88,94,95
Tona et al.96 evaluated the role of MPI as a marker of long-term allo-
graft dysfunction in 154 patients and found a progressive increase in
MPI during long-term follow-up in HT patients with preserved LV
systolic function. MPI resulted higher in patients with multiple rejec-
tion episodes but no correlation was found with the occurrence of
CAV.
Usually, DTI parameters are useful to improve the accuracy of the
assessment of LV diastolic function.97,98 However, in HT patients
the role of myocardial velocities should be interpreted with caution,
because velocities may be affected by the exaggerated translation
motion of the transplanted heart.99 Similarly to transmitral LV filling
parameters, several studies have looked into the ability of DTI para-
meters to predict acute GR. In normal HT patients, LV e′ and s′ wave
velocities tend to be low in the first weeks after transplantation and
Table 3 Continued
AV, aortic valve; CW, continuous wave; IAS, inter-atrial septum; IVC, inferior vena cava; IVS, interventricular septum; LV, left ventricular; MV, mitral valve; PW, pulsed wave; RA, right
atrium; RV, rightventricle; TV, tricuspid valve.
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then they increase gradually. After 1 year, DTI velocities in HT pa-
tients tend to be lower compared with the normal population.72
Dandel et al.87 and Puleo et al.83 found a strong association between
the reduction of e′ wave velocity and episodes of acute GR and CAV,
whereas Stengel et al.86 failed to confirm this finding. Due to high
specificity of DTI parameters, severe rejection could be safely ex-
cluded in the presence of a mitral annular a′ wave velocity .9 cm/
s or,10% reduction in diastolic mitral annular motion velocities.86,87
Similarly, Sun et al.71 described a large cohort of HT patients (264
patients with.400 echocardiographic studies performed) followed
up to 3 years after HT. Based on EMB results, patients were divided
into no rejection (ISHLT grade 0 and 1a) and rejection (ISHLT grade
1B or higher) groups. The authors found that several echocardio-
graphic parameters were statistically different between the two
groups. Patients in the rejection group showed more pericardial ef-
fusion (but with a high prevalence of pericardial effusion in both
groups), shorter IVRT (,90 ms), and greater peak velocity and dur-
ation of Ar wave and a′ wave at both septal and lateral LV walls.
However, the authors could not confirm the previous results83,87
on e′ wave reduction as a marker of acute GR, probably because
of the different definition of the rejection group (in Dandel’s study,
acute GR was defined as more than Grade 2 ISHLT rejection score).
Notably, there was a significant correlation between the number of
abnormal echocardiographic parameters and rejection grade. On
the other hand, a completely normal echocardiographic examin-
ation provided a high negative predictive value for detecting acute
GR at EMB. Mankad et al.84 combined peak systolic wave Doppler
(s′ wave) together with peak diastolic e′ wave velocity (evaluated
at lateral mitral annulus) in a new index, the peak-to-peak mitral an-
nular velocity. They found that values equal or higher than 135 mm/s
have a sensitivity of 93%, specificity of 71%, and a negative predictive
value of 98% in excluding acute GR (defined as greater than grade 1B
Table 4 Doppler tracings and measurements to be routinely performed in patients who underwent heart transplant
CW, continuous wave; LVOT, left ventricular outflow tract; PW, pulsed wave; TVI, time-velocity integral.
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ISHLT rejection score at EMB). Palka et al90 tested the hypothesis
that during acute GR, there is an alteration of early diastolic untwist
mechanisms of the LV and that this alteration may affect the RV too.
Thus, they tested the differences in diastolic movements of LV and
RV walls, by measuring timing differences between onset of early
diastolic mitral inflow velocity (E) and onset of e′ velocity at lateral
annulus, at septal annulus (e′ sep), and at tricuspid annulus (e′ tri).
They found that increased time differences between the onset of
E and e′ septal annulus waves and between the onset of e′ of RV
and LV lateral wall waves could help to discriminate patients. How-
ever, none of the evaluated parameters were significant enough to
be used as a surveillance variable.
Finally, Bader et al.,94 in a prospective study involving 54 HT pa-
tients did not find any echocardiographic parameters to be able to
reliably predict acute GR assessed by EMB, and this result was
confirmed by another smaller study.100 In conclusion, constant
DTI velocities (e.g. e′ change ,10% compared with baseline)
and high DTI velocities (e.g. e′ .16 cm/s) seem to have good
accuracy to exclude (more than detect) acute GR, with a negative
predictive value of 92%. However, these parameters need further
validation.
Echocardiographic evaluation of LV systolic and diastolic function
is of great importance to detect GR. However, there is large dis-
cordance among the different studies. Alterations of diastolic and/
or systolic function may be due to rejection, or other cardiac con-
ditions like ischaemia, hypoxia, and sepsis.101 Therefore, the pres-
ence of alterations in LV function has an important role in the
assessment of prognosis in HT patients, but it is not an accurate
marker of GR or CAV. Some groups are proposing echocardio-
graphic scores to rule out active rejection;102 however, there is a
need for more extensive studies with larger sample sizes before
these scores could be implemented in clinical practice.
Recommendations
Obtain a comprehensive echocardiographic study at 6 months from
the cardiac transplantation as a baseline and make a careful
quantitation of cardiac chamber size, RV systolic function, both
systolic and diastolic parameters of LV function, and pulmonary
artery pressure. Subsequent echocardiographic studies should be
interpreted in comparison with the data obtained from the 6-month
study. An echocardiographic study, which shows no change from
the baseline study, has a high negative predictive value for GR. There
is no single systolic or diastolic parameter that can be reliably used
to diagnose GR. However, in case several parameters are abnormal
the likelihood of GR increases. When an abnormality is detected,
careful revision of images of the present and baseline study
(side-by-side) is highly recommended.
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Table 5 Recommended measurements to be reported (recommended acquisition technique) in echocardiographic
studies obtained from heart transplant patients
Cardiac structure Mandatory measurements Optional measurements
Left ventricle End-diastolic, end-systolic volumes (2D biplane)
Ejection fraction (2D biplane)
Interventricular septum and infero-lateral wall thicknesses
(2D or 2D guided M-mode)
Lateral s and e′ wave velocities (DTI)
Global longitudinal strain (STE)
End-diastolic, end-systolic volumes (3D)
Ejection fraction (3D)
Mass (3D)
Myocardial performance index (Doppler)
Right ventricle TAPSE (M-mode)
Fractional area change (2D)
Free wall thickness
Free wall s wave velocity (DTI)
Free wall longitudinal strain
End-diastolic, end-systolic volumes (3D)
Ejection fraction (3D)
Myocardial performance index
Mitral valve E and A wave velocities (PW Doppler)
Semi and quantitative assessment of severity of regurgitation
(vena contracta diameter, E wave velocity, PW pulmonary
veins, PISA)
Mitral annulus (3D)
Left/right atrium Volume (2D)
Pulmonary vein velocity (PW)
Volume (3D)
Aorta Root diameter (2D)
Diameter at the suture line (2D)
Ascending aorta diameter (2D)
Aortic arch diameter (2D)
Tricuspid valve Semi-quantitative assessment of severity of regurgitation
(vena contracta, PISA radius)
Systolic atrioventricular gradient (CW Doppler)
Morphology (3D)
Annulus size (3D)
Inferior vena cava Expiratory diameters and respiratory collapse (2D)
Pericardium Presence and semi-quantitative assessment of severity and
extent of effusion
2D, two-dimensional echocardiography; 3D, three-dimensional echocardiography; CW, continuous-wave Doppler; DTI, Doppler tissue imaging; PW, pulsed wave; STE, speckle
tracking echocardiography; PISA, proximal isovelocity surface area; TAPSE, tricuspid annular plane systolic excursion.
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RV geometry and function
Right heart failure is a common and much feared complication after
HT, being the single most important cause of death in the early post
period, together with acute GR.5,103,104 Immediately after HT, the
RV cavity size increases due to afterload mismatch with the relative-
ly high pulmonary pressures of the recipient. Indeed, normalization
in RV cavity size is expected the following weeks along with the
progressive reduction of pulmonary resistances.105 Impaired RV
longitudinal systolic function measured by TAPSE, DTI, and RV frac-
tional area change106 is also present in all HT patients in the early
weeks after HT, and two-thirds of HT patients show a partial recov-
ery of RV longitudinal function during the first year, even if TAPSE
remains significantly lower compared with normal.107 The incom-
plete recovery of RV systolic function after HT can be explained
by pre-transplant pulmonary pressures, increased post-transplant
pulmonary gradient, significant tricuspid regurgitation, and
prolonged ischaemia time. However, it is well established that
the RV longitudinal function is not a sensitive parameter of global
RV function after cardiac surgery.108 Recent studies on HT
patients suggest that TAPSE and DTI may be reduced due a
distorted anatomy in the context of a normal overall RV function
and EF.109,110
Recommendations
Assess RV size and function at baseline using several parameters, which
do not exclusively evaluate longitudinal function. At follow-up
echocardiogram, all these parameters should be compared with the
baseline values. 3D echocardiography may provide a more accurate
and comprehensive assessment of RV size and function.
Atrial geometry and function
Atrial geometry and function of the transplanted heart are directly
related to the surgical technique. In patients who underwent HT
using the standard technique, a unique morphological shape is
visualized by echocardiography (best seen in the apical four-
chamber view) as an enlargement of the long-axis dimension of
the atria with a ridge at the site of anastomosis (Figure 2A and B).
In patients who underwent HT using the bicaval or total orthoto-
pic HT techniques, the atrial geometry and function are better
preserved.21,22,26
Recommendations
Due to the unpredictable shape of atria in transplanted patients, atrial
volume should be measured using the discs’ summation algorithm
(biplane algorithm for the left atrium) or 3D echocardiography.
Cardiac valves
Tricuspid valve
Tricuspid valve regurgitation is the most common single valve dis-
ease after HT. It may result from multiple pathophysiological me-
chanisms. In the first weeks after HT, tricuspid regurgitation is
usually secondary to pulmonary hypertension. Its severity often de-
creases spontaneously as pulmonary resistance decreases. Other
frequent causes of tricuspid regurgitation are persistent high pul-
monary pressures, tricuspid annulus enlargement secondary to RV
dilation, lesion of valve apparatus during EMB, acute GR, papillary
muscle dysfunction, and alterations in right atrial contraction with
functional impairment of the valvular apparatus.111 The surgical
technique used for HT seems to influence the occurrence of
tricuspid regurgitation because of the alteration of right atrial
morphology.112
Aortic and mitral valves
Structural alterations of left-sided valves are uncommon after HT,
and changes in morphology and dimension of these valve structures
have not been associated with acute GR. Rates of mitral regurgita-
tion are slightly higher than the aortic regurgitation (attributed to
Table 6 Advanced methodologies that may be useful during follow-up of patients who underwent heart transplant
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Method (parameter cut-off value) Gold standard
(EMB score)
Sensitivity (%) Specificity (%) NPV
Angermann et al.75 52 (18%a) Integrated backscatter
(PW 2D-IB increase .1.5 dB)








Puleo et al.83 121 (13%a) PW-DTI (e′ of inferior wall ,16 cm/s) Grade ≥ 3A 76 88 96
Mankad et al.84 78 (18%a) Colour-coded TDI
(combined peak MV systolic and peak
diastolic velocity ,135 mm/s)









Moidl et al.85 94 (20%a) Automated border detection
(peak filling rate ,4.0 EDV/s)









Stengel et al.86 41 (39%a) PW-DTI
(Aa of lateral MV annulus ,8.7 cm/s)
Grade ≥ 3A 82 53 82


























40 (50%) MPI increase ≥20% from baseline
evaluation
Grade ≥ 3A 90 90
Dandel et al.89 190 (17%a) PW-DTI
(Sm of basal posterior wall
reduction ≥10%)









Palka et al.90 44 (27%a) PW and colour M-mode TDI
(e′ of septal MV annulus ,12 cm/s)
(peak late IVR MVGc .0.1/s)
(onset E wave – onset
Emedd. 235 ms)


















2D and standard Doppler
(≥2 among: PE, IVRT ,90 ms
E/A .1.7)
Post-OHT ≤ 6 months
Post-OHT. 6 months
PW-DTI (Aa of septal/lateral











Marciniak et al.91 31 (32%a) Colour DTI
(mild-LVPW radial peak systolic
strain ≤30%)
(mild-LVPW radial peak systolic








Aa, peak late diastolic velocity; acute GR, acute graft rejection; dB, decibels; Ea, peak early diastolic velocity; EDV, end-diastolic volume; Em, peak early diastolic wall motion velocity;
EMB, endomyocardial biopsy; OHT, orthotropic heart transplantation; IVRT, isovolumetric relaxation time; LVPW, left ventricle posterior wall; MPI, myocardial performance index;
MV, mitral valve; NPV, negative predictive value; PE, pericardial effusion; PW 2D-IB, pulsed-wave 2-dimensional-integrated backscatter; Sm, peak radial systolic velocity; SR, strain
rate; TDI, tissue Doppler imaging; TEm, early diastolic time—from onset of second heart sound to the peak of the early diastolic wave Em; TSm, systolic time—from onset of first
heart sound to the peak of the systolic wave Sm.
aPrevalence of acute GR based on the percentage of biopsies with acute GR defined by the EMB score.
bClinically relevant acute GR defined as EMB grade .2 plus Grades 1A and 1B when accompanied by clinical symptoms.
cPeak late isovolumic relaxation myocardial velocity gradient of the LV posterior wall.
dTiming difference between onset of mitral early diastolic velocity (E wave) and early diastolic septal MV annulus velocity (EMed).
eTiming difference between onset of early diastolic velocity, a lateral tricuspid (ETric) annulus, and an LV early diastolic lateral MV annulus velocity (EMitr).
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oedema of the papillary muscles) but tend to decrease over time
and it is usually mild mitral regurgitation.73,113
Recommendations
Tricuspid regurgitation should be looked for and properly assessed in
all echocardiographic studies. In case of significant changes in
severity of tricuspid regurgitation during follow-up, a 2D/3D and
colour Doppler assessment of its severity and mechanisms should
be performed. Aortic and mitral valves should be evaluated
according to current recommendations.
Aorta and pulmonary artery
The anastomoses of the donor heart to the aorta and pulmonary
artery can be visualized (Figure 6, left panel). In the normal trans-
planted heart, Doppler flow velocities at the aortic and pulmonic
level are usually normal. Occasionally, there is a mismatch between
the diameter of the donor and recipient proximal pulmonary arter-
ies and the suture line in the proximal pulmonary artery offers an
aspect of ‘pseudo-narrowing’. However, no significant gradient is
usually detected by Doppler. The aortic anastomosis may also be
a site of potential surgical complications. An echocardiographic
evaluation of the aorta assessing diameters and potential wall thin-
ning or leaking are recommended. Few reports have described the
occurrence of aortic rupture, pseudoaneurysms, aneurysms, or
dissection related to compliance mismatch, flow turbulence, and
systemic hypertension.114
Superior and inferior vena cavae
Special attention should be paid to the superior vena cava, particu-
larly in patients operated with non-standard surgical technique,
since stenosis at the level of the surgical anastomosis has been
described in 2.4% of these cases.24
Pericardium
Documentation of new pericardial effusion has been reported to
be associated with GR.115 However, the presence of pericardial
effusion per se is not due to GR and its high prevalence in HT
patients, as an early response to surgical ‘injury’ or as compensa-
tion for differences in volumes between the recipient and the do-
nor heart size, results in low sensitivity and specificity to detect
GR.71 It is seen in approximately two-thirds of patients at 3 months
after HT, and in 25% of patients at 6 months, independent of
GR status.71
A localized intrapericardial haematoma may occur early or late
after open heart surgery and not uncommonly is localized anterior
and lateral to the right atrium making the diagnosis with trans-
thoracic echocardiography challenging. If the haematoma is large
or if it is an expanding one, it may compress the right atrium and
cause haemodynamic impairment (e.g. low output state) resembling
acute GR.
Recommendations
Pericardial effusion should be serially evaluated regarding extent,
location, and haemodynamic impact. In case of newly detected
pericardial effusion, GR should be considered taking into account
the overall echocardiographic assessment and patient evaluation.
Advanced echocardiography
Deformation imaging (speckle tracking
and Doppler TISSUE imaging)
Strain and strain rate (SR) are parameters of myocardial deform-
ation. First assessment of strain and SR was derived from DTI vel-
ocity data, and several studies evaluated diagnostic accuracy of
these parameters in OHT patients.91,116,117 Overall, the majority
of the studies found that, even if conventional echocardiographic
examination (including DTI) and right heart catheterization did
not reveal any significant changes compared with previous studies,
global longitudinal peak systolic strain (GLS) was reduced in patients
with histologically proven acute GR. Moreover, segmental longitu-
dinal strain was reduced in LV segments, which showed inducible
Figure 6 Two-dimensional echocardiography acquisitions focused on the ascending aorta and on the pulmonary artery. The suture lines could
be easily identified. Arrow, suture lines; Ao, aorta; LA, left atrium; PA, pulmonary artery; PV, pulmonary valve; RA, right atrium; RV, right ventricle.
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wall motion abnormalities during stress test, and strain values could
predict CAV. This may be explained by the fact that the regional
changes induced by patchy rejection may not be large enough to
alter global LV function indices, as rejection can be a non-uniform
process.91 This also explains the relative insensitivity in detecting
,Grade IIB rejection using global LV function parameters. In the
study by Marciniak et al.,91 the authors postulated that subclinical
myocardial modifications secondary to early acute GR are best
detected by techniques that do not rely on reference points exter-
nal to the heart to be able to detect regional changes in systolic func-
tion. They found that radial peak systolic strain was significantly
reduced in the group with EMB-proved rejection. However, only
regional strain/SR from the LV lateral wall was predictive with acute
GR, and not the strain/SR from the septum, probably due to para-
doxical septal motion that is common after cardiac surgery.
2D-Speckle tracking echocardiography (STE) is an echocardio-
graphic technique that overcomes several limitation of DTI derived
strain/SR (Figures 7 and 8). This technique has been proved to be
accurate for the quantification of myocardial deformation, and it
has already been validated in special subset of patients as an early
marker of myocardial dysfunction.118 The first studies of STE in
HT have been conducted in rats in which both global strain and
peak systolic or diastolic strain were significantly reduced in graft
with alloimmune rejection, while LV EF and fractional shortening
did not show any difference between hearts with and without rejec-
tion.119 The study by Eleid et al.120 was the first one to use STE to
assess myocardial function in HT patients. During a 3-year follow-up
of 51 HT patients, they were able to show that all patients showed a
reduced GLS immediately after HT, but those who did not improve
their GLS during follow-up experienced higher incidence of death
and cardiac events. These results were independent from biopsy-
detected acute GR, suggesting that STE is able to detect early and
subtle alteration of LV systolic function, which may carry a poor
prognosis even in the absence of detectable acute GR.
Many studies demonstrated that strain/SR measurements are
abnormal in many clinical settings with preserved LV EF; thus, it is
uncertain whether the lower GLS values found in transplanted heart
recipients represent normal values of this population or are the first
subtle alterations that consequently lead to myocardial dysfunc-
tion.121 – 123 Nevertheless, these studies confirm that longitudinal
strain values remain stable (even if lower in absolute values com-
pared with general population) over the years and therefore a
reduction over time of such parameters must be interpreted as
pathological. Accordingly, Lisi et al. described a case of biopsy-
proven acute GR associated with marked reduction in longitudinal,
radial, and circumferential strain, with no alteration of other echo-
cardiographic parameters, and complete recovery of myocardial
deformation parameters after appropriate immunosuppressive
therapy and regression of acute GR at the biopsy.124 Table 8 sum-
marizes the results of the different studies which tested the accuracy
of STE in detecting acute GR.
In 167 patients studied with STE during the first weeks after trans-
plantation, GLS has been reported to be an independent predictor
of 1-year mortality. Using a cut-off value of 29%, the sensitivity was
Figure 7 Computation of peak LV GLS by using the speckle tracking technique on three conventional apical views: four-chamber (left, upper
panel), two-chamber (right, upper panel), and apical long axis (left, lower panel). LV segmental values of longitudinal strain are displayed both as
numbers and as parametric colorization on a bull’s eye display (right, lower panel).
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73% and the specificity was 91%. However, because the causes of
death in the cohort were various (from acute GR to CAV, HIT,
and sepsis), no suggestion can be made on the relation between
low GLS and the presence of acute GR and/or CAV at autopsy.
Moreover, there were no differences in GLS, early after HT, among
patient who experienced rejection within the first year and in those
who did not.126 Therefore, from this study, GLS can be regarded as a
predictor of poor clinical outcome but not as a sensitive marker of
rejection.
Recently, an echocardiographic rejection score was proposed
considering a multiparametric evaluation according to the formula
[(PWT + LVMI) – (Lat-1 + Sep-TS)] where PWT (posterior
wall thickness measured in mm); LVMI (LV mass index in g/m2);
Lat-1 (lateral peak systolic strain); and Sep-TS (septal time to systole
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Table 8 Accuracy of the different parameters obtained with speckle tracking echocardiography to detect acute
graft rejection







Sensitivity (%) Specificity (%) Predictive
accuracy (%)
Sato et al.125 301 (8.9%) 25% reduction in LV torsion
values compared with
baseline values
Grade ≥ 2 73.7 95.1 92.9
Kato et al.117 396 (11.3%) Systolic 1 227.4%
Diastolic SR 22.8 s21






Marciniak et al.91 106 (16.9%) LV PW radial 1 ≤ 30%
SR , 3.0 s21






E, strain; GR: graft rejection; LV, left ventricle; PW, posterior wall; SR, strain rate; STE, speckle tracking echocardiography.
aPrevalence of acute GR based on the percentage of biopsies with acute GR defined by the EMB score.
bISHLT 1990 classification criteria for acute GR.1
Figure 8 Computation of peak RV GLS by using the speckle tracking technique on a conventional four-chamber apical view (left, upper panel).
The regional strain values are displayed both as regional strain/time curves (right panel) and in an M-mode parametric colourization (left, lower
panel).
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in ms).102 This score has been proved to be useful to discard an acute
GR episode (with 100% negative predictive value), when the result is
0.102 Further studies are needed to prove the utility of this score as a
screening tool to rule out the presence of acute GR and avoid an
EMB.
Recommendations
GLS is a suitable parameter to diagnose subclinical allograft
dysfunction, regardless of aetiology, by comparing the changes
occurring during serial evaluations. Evaluation of GLS could be used
in association with EMB to characterize and monitor an acute GR or
a global dysfunction episode.
Stress echocardiography
Stress echocardiography has been reported to increase the specifi-
city in detecting CAV. Dobutamine has been the most frequently
used pharmacological stressor and a sensitivity between 70 and
80% to detect significant CAV at coronary angiography has been re-
ported (Table 9).127 Due to the diminished heart rate response to
exercise, related to cardiac denervation state, exercise protocols
have a limited sensitivity of 15–33%.128,130 When intimal thickening
by IVUS is used as the gold standard, dobutamine stress echocardi-
ography increases its specificity up to 88%137,140 Even considering
non-focal and non-significant stenotic disease, the sensitivity of do-
butamine stress echocardiography remains high.127,133 Deterior-
ation between serial stress echocardiography tests yields an
increased risk of events, compared with no deterioration, with a
relative risk of 7.3.140 A positive dobutamine test was found to be
an independent predictor of cardiac events or death in a 4-year fol-
low up study by Bacal et al.141 On the other hand, a negative stress
test indicates a low likelihood of a prognostically relevant CAV and
low rate of occurrence of major adverse cardiac event at
1 year.61,140 Quantitative analysis of segmental LV function, consid-
ering a peak systolic longitudinal strain rate increase of ,0.5/s at
peak stress test as a pathological response, improves the sensitivity
to 88% for detecting any angiographic abnormalities and with nega-
tive predictive value of 92%.116 A post-systolic strain index.34% at
peak stress was reported to be the best parameter to detect
CAV.116 Combination of myocardial contrast echocardiography
with quantitative assessment of myocardial perfusion during dobu-
tamine stress test has been reported to increase the sensitivity from
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Table 9 Accuracy of stress echocardiography for the diagnosis of CAV
Study Patients
(prevalence of CAV)
Stress Reference for CAV Sensitivity (%) Specificity (%)
Collings et al.128 51 (27%) Exercise Angiographya 29 82
Mairesse et al.129 37 (11%) Exercise Angiographyb 0 97
Cohn et al.130 51 (51%) Exercise Angiographya/IVUSc 33/15 85
Ciliberto et al.131 80 (31%) Dipyridamole Angiographya 100 72
Ciliberto et al.132 68 (37%) Dipyridamole Angiographya 100 87
Akosah et al.133 41 (51%) Dobutamine Angiographya 100 41
Herregods et al.134 28 (50%) Dobutamine Angiographyb 50 71
Akosah et al.135 45 (53%) Dobutamine Angiographyb 96 52
Derumeaux et al.127 41 (38%) Dobutamine Angiographya 100 77
Derumeaux et al.136 64 (47%) Dobutamine Angiographya 100 NR
Spes et al.137 46 (26%) Dobutamine Angiographyb/IVUSd 83/79 56/83
Akosah et al.138 22 (32%) Dobutamine Angiographya 100 59






Spes et al.140 109 (46%) Dobutamine Angiographyb and/or IVUSd 72 88
Bacal et al.141 39 (38%) Dobutamine Angiographya 64 91




Rodrigues et al.142 35 (29%) Contrast-enhanced Angiographya 70 96
Tona et al.143 73 (47%) Contrast-enhanced Angiographya 82 87
CAV, cardiac allograft vasculopathy; IVUS, intravascular ultrasound.
aCoronary stenosis .50% in at least 1 vessel.
bAny angiographic abnormalities including luminal irregularities.
cStanford classification Grade III to IV.
dApproximating to Stanford classification Grade III– IV; angiographic luminal irregularities or intravascular ultrasound (IVUS) severity approximating to Stanford classification
Grade III– IV.
eConventional regional wall motion analysis.
fRegional peak systolic strain rate analysis.
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71 to 86% with a 91% specificity.144 Adding contrast infusion to as-
sess myocardial perfusion during dobutamine stress test was con-
firmed to be moderately sensitive (70%) and highly specific (96%)
for the presence of ≥50% coronary stenosis at angiography.142
However, correlation of detected perfusion defects with coronary
territory was poor except for the left anterior descending artery, in
addition, the test failed to identify multivessel disease. The main con-
tribution of stress echocardiography in the management of the post-
transplant patients is to assess their prognosis. Indeed, patients with
negative dobutamine stress echocardiography have ,3% risk of
experiencing major adverse cardiac events over the following year.
In theoretically unsuitable heart donors with brain death, pharma-
cologic stress echocardiography (either dipyridamole or dobuta-
mine) has been used to exclude occult coronary artery disease or
cardiomyopathy to extend the numbers of heart donors among
the elderly, patient with stunned hearts or those with previous
history of cardiac disease with a normal test result.145 – 147
Quantitative myocardial perfusion by contrast
echocardiography
An advantage of quantitative contrast myocardial perfusion echo-
cardiography is that it provides both structural (rBV—the vascular
density relative to the surrounding tissue) and functional (B—micro-
vascular conductance index) parameters, which actually constitute
the microvasculature at the arteriolar and capillary level.148 An
rBV value ,0.14 at rest can accurately detect severe CAV with a
sensitivity of 90% and specificity of 75%.149 However, because quan-
titative analysis is a time-consuming procedure, requiring specialized
trained personnel and because the software analysis is not wide-
spread, myocardial perfusion imaging is currently assessed semi-
quantitatively by visual analysis.
Echocardiographic evaluation of coronary flow reserve
Direct measurement of coronary blood flow velocity at rest and
during adenosine stress in the distal left anterior descending artery,
using transthoracic Doppler echocardiography, could be applied
and used to calculate the ratio between peak test velocity/baseline
velocity which correlates with invasively measured coronary flow
reserve (CFR). A CFR ≤ 2.7 by transthoracic echocardiography
has demonstrated good accuracy (87% specific and 82% sensitive)
for detecting CAV.143 In addition, echocardiographic CFR has
been reported to have prognostic value for CAV-related major car-
diac events (3.3 relative risk of death, myocardial infarction, congest-
ive heart failure, or need for percutaneous intervention at a mean of
19 months).150 A CFR, 2.9 can detect a maximal intimal thickness
of ≥0.5 mm by IVUS with 80% sensitivity, 100% specificity, and 89%
negative predictive value.151
Recommendations
Dobutamine stress echocardiography might be a suitable alternative to
routine coronary angiography to assess CAV at centres with
adequate experience with the methodology. CFR and/or contrast
infusion to assess myocardial perfusion can be combined with stress
echocardiography to improve the accuracy of the test.
Integrated backscatter
Integrated backscatter is an echocardiographic technique based on
myocardial acoustic properties, which aims to characterize myocar-
dial tissue. Initial studies reported higher values of end-diastolic in-
tegrated backscatter measured at the LV infero-lateral wall in Grade
1B, 2, or 3 acute GR, compared with Grade 0. Backscatter signal
measurements in the LV infero-lateral wall were more discrimin-
atory than those measured in the anterior septum, with a 88% sen-
sitivity and 89% specificity for detecting ≥1B grade acute GR (1.5 dB
increased backscatter signal), and 92% sensitivity and 90% specificity
for detecting ≥3 grade (5.5 dB increased backscatter signal).75
Recommendations
Integrated backscatter is highly dependent on acoustic window, it is
technically demanding and with high inter- and intra-observer
variability. Therefore, integrated backscatter is not recommended
for clinical purposes.
Three-dimensional echocardiography
There are two studies evaluating the role of three-dimensional
echocardiography (3DE) in HT patients.110,152 Assessment of LV
mechanical dyssynchrony by 3DE (time to minimum systolic volume
adjusted by R–R interval length in a 16-segment model of LV)
showed a 95% sensitivity and 73% specificity for predicting acute
GR.152 In another study, 3DE has been used to assess RV geometry
and EF, suggesting that it is a more accurate methodology to per-
form a functional evaluation.110
According to recent studies, 3DE should have an important role
in assessing HT patients since it has been reported to be more ac-
curate and reproducible than two-dimensional echocardiography in
quantitating LV and RV volumes, LV mass, and atrial volumes. More-
over, during stress echocardiography, 3DE may improve the assess-
ment of regional wall motion, possibly improving the accuracy of
acute GR and CAV screening.153,154
Recommendations
In echocardiography laboratories equipped with 3DE scanners and
specific expertise with the technique, 3DE may be a suitable
alternative to conventional 2D echocardiography to assess the size
and the function of cardiac chambers. 3DE measurement of LV and
RV size and function are more accurate and reproducible than
conventional 2D calculations. Cardiac chamber volumes obtained
with 3DE cannot be compared with those obtained with
two-dimensional echocardiography.
Echocardiography to guide EMB
Traditionally, fluoroscopy has been used to guide EMB, but this im-
aging modality has a number of limitations, including cumulative ra-
diation exposure, limited portability, and the limited area of access
(interventricular septum) for biopsy. In contrast, echocardiography
provides greater portability, eliminates radiation exposure, provides
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important information about cardiac function, and safely allows bi-
opsy of any area of the RV, including the free wall and apex.155
Several observational studies demonstrated the benefits of echocar-
diography over fluoroscopy in guiding EMB: (i) more adequate po-
sitioning of the bioptome against the septum;155 – 157 (ii) higher
percentage of adequate biopsy samples;158 (iii) less biopsy-related
complications;158,159 and (iv) less radiation exposure.155 – 157,159
However, there is no randomized study to prove the superiority
of echocardiography over fluoroscopy.
Recommendations
In experienced centres, echocardiography might be an alternative to
fluoroscopy to guide EMB, particularly in children and young
women, since it avoids repeated X-ray exposure and permits
visualization of soft tissues and safer performance of biopsies of
different RV regions.
Role of other imaging modalities
Invasive imaging
Coronary angiography
Coronary angiography remains the main screening tool for CAV in
most centres, also being able to guide management, and to predict
adverse events in HT recipients. The latest guidelines for manage-
ment of HT recipients consider coronary angiography as the gold-
standard method to detect CAV (Class I, evidence C). The Stanford
classification system is used to describe the morphology of coronary
lesions from a discrete atherosclerosis to concentric arterial obliter-
ation.160,161 However, coronary angiography can underdiagnose
both the prevalence and extent of CAV due to the vascular remod-
elling, involving the entire coronary tree, which in an early stage
does not necessarily reduce the luminal diameter.162,163 Therefore,
angiograms should be interpreted serially as new and concentric
lesions may be missed on one-time angiograms.
Invasive CFR
Evaluation of invasive CFR may provide additional information
about the presence and severity of CAV, and may identify early
CAV in patients without angiographically evident narrow-
ings.164,165 However, there is little evidence that invasive CFR is
of any prognostic relevance.61 A possible explanation may be re-
lated to the uniformly high resting heart rate, which impairs the re-
liability of the CFR assessment in detecting microvascular
impairment. Furthermore, the presence of LV hypertrophy and
higher donor ages independently contribute to a reduced CFR in
patients after HT.166 In HT patients, the reduction in CFR is due
to elevated baseline flow velocities rather than to a change in
hyperaemic flow velocities and should be taken into account for
the test interpretation.
Recently, the instantaneous wave-free ratio has been proposed as
an alternative invasive pressure-only index of coronary disease se-
verity.167 Because instantaneous wave-free ratio is calculated under
baseline coronary haemodynamics—precluding induction of
hyperaemia168—it emerges as a potential tool to investigate sten-
osis in transplanted patients. Instantaneous wave-free ratio could
circumvent the limitations of FFR in such sub-population of patients
with known microvascular disease and variable response to coron-
ary vasodilators.169
Intravascular ultrasound
IVUS has emerged as the gold standard for early detection of CAV
due to high-resolution images of the cross-section of the vessel. It
allows the accurate quantitative assessment of lumen size, intimal
thickening, vessel wall morphology, and composition.162,170 Numer-
ous studies have demonstrated that even in the presence of a normal
coronary angiogram, IVUS findings are predictive of CAV and are
reliable prognostic markers of subsequent mortality and non-fatal
major adverse cardiac events at 1 and 5 years after HT.171–173 Indeed,
an intimal thickness measured by IVUS correlated with microvascular
impairment, even when FFR and angiograms were normal.174 There-
fore, the guidelines for the management of heart transplant patients
state that ‘IVUS in conjunction with coronary angiography with a
baseline study at 4–6 weeks and at 1 year after HT is an option to
exclude donor coronary artery disease, to detect rapidly progressive
CAV, and provide prognostic information’, giving a class of recom-
mendation IIa and level of evidence B (Table 10).
Optical coherence tomography
Optical coherence tomography is an optical signal acquisition and
processing method, typically employing near-infrared light, which
captures micrometer-resolution, 3D images from within optical
scattering media (e.g. biological tissue). The use of relatively long
wavelength light allows it to penetrate into the scattering coronary
wall providing an even higher spatial resolution than IVUS and, in
theory, an earlier detection of morphological changes in the coron-
ary wall. Good correlation with IVUS for measurement of maximal
intimal thickness and luminal area has been demonstrated, with a
lower inter-observer variability.176
Recommendations
Currently, coronary angiography is the gold-standard method for the
detection of CAV.
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Table 10 Stanford classification of CAV severity
on IVUS
Class I Class II Class III Class IV
Severity Minimal Mild Moderated Severe
Intimal thickness ,0.3 mm ,0.3 mm 0.3–0.5 mm .1.0 mm




CAV, cardiac allograft vasculopathy; IVUS, intravascular ultrasound.
Reproduced from St Goar FG et al.175
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Nuclear cardiac imaging
Considerable variations in study methodologies (different stressors
protocols and tracer agents, time of the evaluation, and variable cri-
teria to diagnose CAV) and results have been found when trying to
evaluate the accuracy of nuclear cardiac imaging in detecting
CAV.177 –184 Despite dobutamine has been reported to be advanta-
geous as a stressor, recent studies demonstrated comparable accur-
acy to stress protocols using dipyridamole.183 – 186 A large study
evaluating dipyridamole-stress Sestamibi SPECT to assess CAV, de-
monstrated 92% sensitivity and 86% specificity to detect significant
vascular disease (luminal narrow ≥50%), and only 56% sensitivity to
detect angiographic abnormalities of any grade.186 Prognostic infor-
mation is also provided from both dobutamine-stress and
dipyridamole-stress SPECT protocols, where dobutamine protocol
demonstrated higher sensitivity and negative predictive value for
major adverse cardiac events.184,186,187 A range of molecular com-
ponents of acute GR has been targeted with radionuclide scintig-
raphy; however, based on the lack of availability of large
multicenter trial results, the conflicting results in published studies
and the high burden of radiation related to this imaging technique,
it can be recommended in clinical practice only in patients unsuitable
for stress echocardiography.188
Recommendations
In patients with inadequate acoustic window and contraindication to
contrast agents, pharmacological SPECT is an alternative imaging
modality to detect CAV in HT patients. However, in centres with
adequate expertise, IVUS in conjunction with coronary angiography
with a baseline study at 4–6 weeks and at 1 year after HT should be
performed to exclude donor coronary artery disease, to detect
rapidly progressive CAV, and to provide prognostic information.
IVUS should also be performed when there is discrepancy between




Computer tomographic (CT) coronary angiography can be em-
ployed to exclude relevant CAV. One possible limitation of this
method is the difficulty to reach the appropriate heart rate neces-
sary to obtain good quality images in OHT patients, since transplanted
hearts are denervated and beat at high heart rate. Scanners that pro-
vide high temporal resolution, such as dual-source systems, provide
Figure 9 Cardiac magnetic resonance acquisitions using different protocols for quantitating changes in myocardial structure and detect
myocardial tissue inflammatory and perfusion alterations.
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more guarantee for sufficient image quality in patients with a persist-
ently high heart rate. The use of CT in the evaluation of CAV has been
reported in the guidelines for the management of HT patients as a
Class IIb recommendation (Level of Evidence: C). This imaging modal-
ity offers the possibility of evaluating the coronary lumen, as well as
the wall thickness and intimal hyperplasia, with a potential for early
CAV detection. CT coronary angiography can detect up to 50%
more coronary segments with increased wall thickness than conven-
tional coronary angiography.189,190 Although relatively high sensitiv-
ities (70–100%) and specificities (81–100%) have been reported in
the detection of significant coronary stenosis, comparative studies
with IVUS or optical coherence tomography to assess its true sensi-
tivity are scarce.61,189–191 Its high negative predictive value to exclude
coronary stenosis makes this technique a possible screening test be-
fore undergoing coronary angiography.190,192–194 Although concerns
regarding the exposure to ionizing radiation and nephrotoxic contrast
remain, exposure generally does not exceed nuclear imaging or inva-
sive coronary angiography, and contemporary scanner technology al-
lows coronary imaging at ever decreasing radiation doses.
In addition, using CT, calcium is detected more frequently than
would be suggested by studies using intravascular ultrasound. It is as-
sociated with the presence of angiographic disease and with some
conventional risk factors for coronary disease. At follow-up, the
presence of coronary calcium was associated with an adverse clin-
ical outcome.195
CT is a powerful imaging technique for undisturbed interrogation
of the cardiovascular morphology, which is particularly effective in
various acute conditions, and when echocardiography cannot be
performed adequately. In more exceptional situations, cardiac CT
can be employed to quantify global LV and RV function. Dynamic
myocardial perfusion imaging during pharmacological vasodilation
allows quantification of myocardial perfusion and may provide a
non-invasive alternative to PET imaging for the detection of micro-
vascular disease in the future.196 – 198
Recommendations
In experienced centres, CT coronary angiography is a good alternative
to coronary angiography to detect CAV. In patients with a
persistently high heart rate, scanners that provide high temporal
resolution, such as dual-source systems, provide better image
quality.
Cardiac magnetic resonance
CMR provides accurate measurements of LV and RV diastolic and sys-
tolic volumes and hence LV and RV EF in addition to its unique ability
to quantitate changes in myocardial structure and detect myocardial
tissue alterations (oedema and fibrosis) secondary to acute GR and
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Table 11 Suggested echo techniques and imaging modalities during planned follow-up visits of heart transplant patients
Imaging modality Technique Class Annotations
Echocardiography Conventional TEE Recommended
3D Reasonable In centres with specific expertise, to assess LV and
RV geometry and function in patients with good
acoustic window
Speckle tracking Reasonable In centres with specific expertise, in patients with
good acoustic window
Contrast LVO Reasonable In patients with insufficient acoustic window
TOE Not recommended
Dobutamine stress echo Recommended In centres with specific expertise, to detect CAV
Coronary flow reserve Reasonable In centres with specific expertise, to detect CAV
Contrast MCE Not recommended
Integrated backscatter Not recommended
Cardiac magnetic
resonance
Reasonable In patients with inadequate acoustic window despite
contrast
CT Reasonable In patients with contrandication to CMR
Coronary angiography Recommended To detect CAV
IVUS Reasonable When there is discrepancy between coronary angio
and non-invasive tests about the presence of CAV
Invasive coronary flow
reserve
Questionable To detect CAV when there is discrepancy between




Reasonable In centres with specific experience
Pharmacological SPECT Either dobutamine or
dipyridamole
Reasonable In patients with inadequate acoustic window and
contraindications to contrast agents
CT coronary angiography Not recommended for routine
clinical use
3DE, three-dimensional echocardiography; CAV, cardiac allograft vasculopathy; CT, computed tomography; IVUS, intravascular ultrasound; LVO, left ventricular opacification;
MCE, myocardial perfusion contrast echocardiography; SPECT, single-photon emission computed tomography; TOE, transoesophageal echocardiography; TTE, transthoracic
echocardiography.
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CAV (Figure 9A and B). T2 relaxation time is the most widely investi-
gated parameter for acute GR screening, showing a significant positive
correlation with rejection severity by histology and ex vivo myocardial
water content.199–201 A longer T2 relaxation time (≥56 ms) had a
97% negative predictive value for detecting significant acute GR (≥
ISHLT grade 2), but only 35% positive predictive value.201,202 Short-
ening of T2 relaxation time during immunosuppressive therapy has
also been reported.200 Data about myocardial signal intensity analysis
with T2-weighted imaging to assess acute GR are inconsistent. Most of
the studies have been performed using technology which were
inferior to current standards in scanner hardware and sequence
design; this may explain why some studies failed to demonstrate
significant difference relative myocardial signal intensity.203
Myocardial inflammatory changes can be detected with the use of
gadolinium (Figure 9C ). An increase in relative myocardial contrast
uptake has been identified in patients with myocardial necrosis on
EMB.204 Estep et al.205 reported that areas of hyper enhancement
are detected in acute GR, and these areas appear to be reduced
in extent after immunosuppressive treatment. However, the pres-
ence and extent of hyper enhancement was not related to EMB
ISHLT grade.202,206 A multi-sequential CMR protocol, combining
‘short tau inversion recovery’ sequence for calculation of oedema
ratio and a T1-weighted spin-echo sequence for assessment of global
relative enhancement, has a potential to exclude GR with a negative
predictive value of 96% but with a low specificity (57%) and a low
positive predict value (23%).207
Stress perfusion CMR with adenosine (Figure 9D) was tested in
two studies, demonstrating reduced myocardial blood flow in pa-
tients with CAV compared with the normal population, allowing
stratification of vascular disease severity.208,209
Recommendations
In patients with insufficient acoustic window, CMR is an alternative to
echocardiography to assess cardiac chamber volumes and function
and to exclude acute GR and CAV in a surveillance protocol.
Future directions in research
Single-centre studies have shown the potentialities of different imaging
modalities to diagnose GR and CAV and to predict outcome in HT pa-
tients. However, these results need to be confirmed by multicenter
outcome studies involving large numbers of patients from and different
institutions. The role of new echo technologies (e.g. speckle tracking
myocardial deformation imaging, 3D echocardiography, non-invasive
CFR, and myocardial perfusion echocardiography), as well as the
role of CMR and CT coronary angiography, in diagnosing GR and
CAV seems to be particularly promising and should be tested in a spe-
cifically designed multicentre trial. This type of trial should not only
test the accuracy of different multimodality protocols to assess HT pa-
tients, but also their safety and cost-effectiveness.
Conclusions
The cohort of long-term survivors of HT is expanding, and the as-
sessment of these patients requires specific knowledge of the
surgical techniques employed to implant the donor heart, the physi-
ology of the transplanted heart, complications of invasive tests rou-
tinely performed to detect GR, and the specific pathologies that may
affect the transplanted heart. A joint EACVI/Brazilian cardiovascular
imaging writing group committee has prepared these recommenda-
tions to provide a practical guide to echocardiographers involved in
the follow-up of HT patients and a framework for standardized and
efficient use of cardiovascular imaging after HT (Table 11).
Conflict of interest: None declared.
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